Atlas Trials

Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

Clinical trial NCT04393506 · COMPLETED

Trial details

NCT number
NCT04393506
Sponsor
Shanghai Jiao Tong University School of Medicine
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Oral CancerVEGFR2 InhibitorProgrammed Cell Death 1 InhibitorInductive Therapy
Start date
2020-04-23
Primary completion
2020-11-02
Enrollment
21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.